CLAIMS

1. A composition comprising a compound of Formula I:



Formula I (Compound 1),

wherein the composition comprises about 0.0001 % to about 0.004% w/w, relative to the weight of Compound 1 in the composition, of each of:

2-Cl-BO (2-Chlorobenzoxazole),

BO-Imp-3 (2-Aminophenol), and

BO-Imp-4 (2-[Bis(1,3-benzoxazol-2-yl) amino]phenol).

2. The composition of claim 1, wherein the compound of Formula I is present at an enantiomeric purity of at least about 98% in the composition.

3. The composition of claim 1, wherein the composition further comprises at least one pharmaceutically acceptable carrier.

4. A crystalline form of the compound of Formula I:



Formula I (Compound 1),

wherein the crystalline form is characterized by an X-ray powder diffraction (XPRD) pattern comprising approximate peak positions (degrees 2θ ± 0.2), when measured using Cu K_α radiation, of 9.6, 15.2, 18.0, 19.4, 23.0, and 31.4, when the XPRD is collected from about 2 to about 42 degrees 2θ.

5. The crystalline form of claim 4, wherein the crystalline form is characterized by an XPRD pattern comprising approximate peak positions (degrees 2θ ± 0.2) of 9.6, 15.2, 15.8, 17.5, 18.0, 19.4, 21.9, 23.0, 24.5, 25.1, 26.4, and 31.4.

6. A composition comprising the crystalline form of claim 4 and at least one pharmaceutically acceptable carrier.